Prasugrel
As of the edition of 20 October 2026, Prasugrel is a small molecule: marketed, first approved in 2009 (EU); acts on P2RY12.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2009
- Kind
- Small molecule
- Brand name
- Effient
- First approved
- 24 February 2009 (EU)
- Approvals on record
- 3 in 2 regions
- Holder of the most recent approval
- Cosette Pharmaceuticals; 2 holders in all
- Registered trials
- 108, 11 stopped early
- Disease areas
- Heart and blood vessels; Inherited and neonatal; Blood and lymph; Hormones; Nutrition and metabolism; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| P2RY12 | P2Y purinoceptor 12 | Q9H244 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 6 | 0 | 1 |
| Phase 1 | 13 | 10 | 0 | 2 |
| Phase 2 | 14 | 12 | 0 | 1 |
| Phase 3 | 29 | 23 | 2 | 2 |
| Phase 4 | 43 | 24 | 10 | 5 |
| All trials | 108 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Applicant and Lead sponsor of trials | 2003 to now |
| Substipharm | Applicant | 2009 to now |
| Cosette Pharmaceuticals | Acquired holder | 2022 to now |